Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab for Macrophage Activation Syndrome in Still's Disease and Systemic Lupus Erythematosus (EMERALD)
jRCT2031220187Completed
- Sponsor
- Sobi
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of emapalumab in macrophage activation syndrome (MAS), haemophagocytic lymphohistiocytosis (HLH), adult-onset Still's disease (AOSD) and 2 more, sponsored by Sobi. Primary endpoint: Complete response at Week 8. Started Mar 2023; status: completed.
02
Drugs
emapalumab
03
Conditions
macrophage activation syndrome (MAS)haemophagocytic lymphohistiocytosis (HLH)adult-onset Still's disease (AOSD)systemic juvenile idiopathic arthritis (SJIA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2031220187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220187.